Pharmacology · Antiparasitic Drugs

Antihelminthic Agents

Benzimidazoles, ivermectin, praziquantel, pyrantel, diethylcarbamazine, and resistance

Benzimidazoles (mebendazole and albendazole) bind helminth β-tubulin at the colchicine site, blocking microtubule polymerization and disrupting mitotic spindle formation, glucose uptake, and intracellular transport — the critical clinical distinction is that albendazole achieves systemic distribution after hepatic activation to its sulfoxide metabolite, while mebendazole remains in the gut lumen and cannot treat tissue-invasive disease.
Ivermectin selectively activates glutamate-gated chloride channels found in invertebrate nerve and muscle but absent from mammalian CNS — irreversible channel opening causes hyperpolarization and flaccid paralysis of the worm; the blood-brain barrier (maintained by P-glycoprotein MDR1) normally protects humans, but MDR1 inhibitors increase CNS penetration risk.
Praziquantel acts by a dual mechanism: at low concentrations it triggers calcium influx causing spastic paralysis, while at higher concentrations it disrupts the worm's tegument (outer membrane) — tegumental disruption exposes cryptic antigens to host immune attack; the single major exception is Fasciola hepatica, which is intrinsically resistant and requires triclabendazole.
Strongyloides stercoralis must be diagnosed and treated before any course of immunosuppression — corticosteroids in a patient with unrecognized strongyloidiasis triggers hyperinfection syndrome (massive larval amplification), which is uniformly fatal if not recognized and treated; ivermectin, not benzimidazoles, is the drug of choice.
In regions where Loa loa is endemic, both ivermectin and diethylcarbamazine are contraindicated in patients with high microfilarial burden (>30,000 microfilariae/mL) — rapid killing of microfilariae causes encephalopathy through microemboli and inflammatory mediator release that can be fatal.

Abbreviations: ATP = adenosine triphosphate · DEC = diethylcarbamazine · GluCl = glutamate-gated chloride channel · MDA = mass drug administration · MDR1 = multidrug resistance 1 (P-glycoprotein) · nAChR = nicotinic acetylcholine receptor · WHO = World Health Organization

Benzimidazoles — Mebendazole and Albendazole

Mechanism

β-Tubulin Binding

Bind selectively to helminth β-tubulin at the colchicine-binding site (higher affinity than mammalian tubulin)
Block microtubule polymerization → arrest mitotic spindle assembly
Disrupts glucose uptake, intracellular vesicular transport, and secretory function
ATP depletion → progressive worm death (not immediate paralysis)
Active against eggs, larvae, and adult worms — useful for reducing transmission
Teratogenic (animal data) — avoid in first trimester; used after second trimester if benefit exceeds risk

Mebendazole vs. Albendazole

Absorption Determines the Clinical Role

Mebendazole: very low oral bioavailability (~1–2%) → stays in GI lumen → effective only for intestinal nematodes; no systemic or tissue effect
Albendazole: hepatically activated to albendazole sulfoxide → systemic distribution → tissue-invasive disease treatable
Albendazole for tissue infections: take with fatty meal (increases absorption 5-fold)
Tissue targets for albendazole: neurocysticercosis (T. solium), cystic echinococcosis, visceral larva migrans, trichinosis
WHO MDA programs: albendazole (single dose, school-age children) for soil-transmitted helminthiasis

Ivermectin — Glutamate-Gated Chloride Channel Activation

Mechanism and Selectivity

Invertebrate-Specific GluCl Channels

Binds GluCl channels at a distinct site in invertebrate nerve and muscle cells
Irreversible channel opening → sustained chloride influx → hyperpolarization → flaccid paralysis → worm death
GluCl channels absent from mammalian CNS — basis of selective toxicity
MDR1 P-glycoprotein in blood-brain barrier normally prevents ivermectin CNS penetration in humans
MDR1 inhibitors (ritonavir, quinidine, verapamil, high-dose ketoconazole): increase CNS penetration risk — CNS toxicity (encephalopathy) reported

Critical Safety — Loa Loa and Strongyloides

Conditions That Change Risk

Strongyloides hyperinfection: ivermectin is drug of choice for Strongyloides stercoralis; screen all patients from endemic areas before starting immunosuppression — hyperinfection with corticosteroids is fatal
Loa loa in co-endemic areas: high microfilarial burden (>30,000 mf/mL) → rapid killing → encephalopathy and death; point-of-care testing for Loa microfilaremia recommended before MDA in Africa
Onchocerciasis: ivermectin is microfilaricidal only at standard doses (does not kill adult worms); annual MDA required for elimination programs
Lymphatic filariasis MDA: ivermectin + albendazole in onchocerciasis-co-endemic regions; DEC + albendazole elsewhere

Praziquantel — Trematodes and Cestodes

Dual Mechanism

Calcium Influx and Tegument Disruption

Low dose: calcium influx → spastic paralysis → worm dislodged from tissue
Higher dose: tegument vacuolization → disruption of outer membrane → exposes cryptic worm surface antigens
Exposed antigens trigger host immune killing — host immune response required for cure
Drug of choice: all schistosomes, intestinal tapeworms (Taenia, Diphyllobothrium), liver flukes (Clonorchis, Opisthorchis), Hymenolepis
Exception: Fasciola hepatica — intrinsically resistant to praziquantel; use triclabendazole

Drug Interactions and Neurocysticercosis Rules

CYP3A4 Induction and Cyst Status

Rifampin (CYP3A4 inducer): reduces praziquantel plasma levels by ~85% — therapeutically ineffective; never co-administer
Corticosteroids: reduce CSF praziquantel penetration — albendazole preferred for neurocysticercosis (better CNS penetration, unchanged by steroids)
Schistosomiasis retreatment: a second course 4–6 weeks later is recommended to catch maturing schistosomula not killed in the first course
Neurocysticercosis: treat viable/enhancing cysts with albendazole + corticosteroid; NEVER treat purely calcified/dead cysts — adds risk without benefit

Pyrantel Pamoate and Diethylcarbamazine

Luminal Nematocide

Pyrantel Pamoate

nAChR agonist — depolarizing neuromuscular blockade → spastic paralysis → worms expelled by peristalsis
Minimal absorption — luminal activity only; not useful for tissue-invasive disease
Active: Ascaris lumbricoides, hookworm (Necator, Ancylostoma), pinworm (Enterobius vermicularis)
Inactive: Trichuris trichiura (whipworm), tapeworms, tissue helminths — use albendazole or mebendazole for whipworm
Safe in pregnancy; OTC for pinworm
Do not combine with piperazine — pharmacodynamic antagonism (piperazine causes flaccid paralysis via GABA; pyrantel causes spastic paralysis via nAChR)

Microfilaricidal

Diethylcarbamazine (DEC)

Modifies surface properties of microfilariae → exposes surface antigens → enhanced host immune clearance (phagocytosis by reticuloendothelial system)
Also direct suppressive effect on microfilarial motility
First-line for lymphatic filariasis (Wuchereria bancrofti, Brugia malayi), loiasis (Loa loa, low burden only), and tropical pulmonary eosinophilia
Contraindicated in loiasis with high microfilarial burden — encephalopathy risk (same as ivermectin)
Contraindicated in onchocerciasis-endemic areas — severe Mazzotti reaction (inflammatory skin/eye reaction from dying microfilariae)
Contraindicated in pregnancy

Drug Selection by Helminth Class

Intestinal nematodes (Ascaris, hookworm, Trichuris): albendazole (single dose, WHO MDA) or mebendazole; pyrantel for Ascaris and hookworm. Strongyloides stercoralis: ivermectin (drug of choice — benzimidazoles inferior). Filarial disease and onchocerciasis: ivermectin (microfilaricidal). Lymphatic filariasis MDA: DEC + albendazole (no onchocerciasis co-endemicity) or ivermectin + albendazole (onchocerciasis co-endemic). Schistosomes and intestinal tapeworms: praziquantel. Fasciola hepatica: triclabendazole (not praziquantel). Neurocysticercosis (viable cysts): albendazole + corticosteroid ± praziquantel. Cystic echinococcosis (Echinococcus): albendazole as surgical adjunct or extended medical therapy.

Critical Safety Rules — Strongyloides, Loa Loa, and Neurocysticercosis

Strongyloides before immunosuppression: eosinophilia plus any planned immunosuppression (steroids, biologic agents, solid organ transplant, chemotherapy) requires Strongyloides serologic testing first. A positive result must be treated with ivermectin before immunosuppression begins — hyperinfection with dissemination is uniformly fatal without treatment. In endemic-area travelers or immigrants with any unexplained eosinophilia, test even without clinical symptoms.

Loa loa high microfilarial burden: both ivermectin and DEC can cause severe, potentially fatal encephalopathy in patients with Loa microfilarial counts above 30,000/mL. In Central and West African MDA campaigns, point-of-care microfilarial testing (e.g., LoaScope) is recommended before administering ivermectin. If Loa co-infection is confirmed and microfilarial burden is high, alternative strategies (apheresis to reduce burden before drug treatment) should be pursued.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 54: Clinical Pharmacology of the Antihelminthic Drugs	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 51: Chemotherapy of Helminth Infections	McGraw-Hill, 2023
Lacey E	The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles	Int J Parasitol. 1988;18(7):885–936
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 51: Chemotherapy of Helminth Infections	McGraw-Hill; 2023
White AC Jr, Coyle CM, Rajshekhar V, et al.	Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America and the American Society of Tropical Medicine and Hygiene	Clin Infect Dis. 2018;66(8):e49–e75
Ottesen EA, Campbell WC	Ivermectin in human medicine	J Antimicrob Chemother. 1994;34(2):195–203
Boatin BA, Richards FO Jr	Control of onchocerciasis	Adv Parasitol. 2006;61:349–394
Pica-Mattoccia L, Cioli D	Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment	Int J Parasitol. 2004;34(4):527–533
Garcia HH, Evans CAW, Nash TE, et al.	Current consensus guidelines for treatment of neurocysticercosis	Clin Microbiol Rev. 2002;15(4):747–756
Aubry ML, Cowell P, Davey MJ, Shevde S	Aspects of the pharmacology of a new anthelmintic: pyrantel	Br J Pharmacol. 1970;38(2):332–344
Gyapong JO, Gyapong M, Yellu N, et al.	Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities	Lancet. 2010;375(9709):160–165
Prichard RK, Basanez MG, Boatin BA, et al.	A research agenda for helminth diseases of humans: intervention for control and elimination	PLoS Negl Trop Dis. 2012;6(4):e1549
Churcher TS, Pion SD, Osei-Atweneboana MY, et al.	Identifying sub-optimal responses to ivermectin in the treatment of river blindness	Proc Natl Acad Sci USA. 2009;106(39):16716–16721
Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE	Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans	Acta Trop. 2010;114(1):1–16